Loyal for Dogs
The first FDA-approved longevity drug — starting with man's best friend
2019
San Francisco, USA
Prescription
loyalfordogs.com
Overview
Loyal developed LOY-001, the first drug to receive FDA \"reasonable expectation of effectiveness\" for lifespan extension in large dogs. This groundbreaking approval opens the regulatory pathway for longevity therapeutics in humans.
Why It's Notable
First-ever longevity drug with FDA pathway. Founded by Celine Halioua. Could unlock human longevity drug development.
How It Works
LOY-001 targets the IGF-1 pathway, which is associated with aging in both dogs and humans. Large dogs have higher IGF-1 and shorter lifespans. By modulating this pathway, the drug aims to extend healthy lifespan by 1-3 years in large breeds.
Key Features
Team & Background
Founded by Celine Halioua. Backed by $58M+ from a16z, Khosla, and others.
Disclaimer: This information is for educational purposes only. Health.AI does not endorse, sell, or receive compensation from any listed product. Always consult your healthcare provider before using any health technology. Product claims are based on manufacturer data and published research at the time of listing.